Literature DB >> 33458809

WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors.

Andrea Scarpino1, László Petri1, Damijan Knez2, Tímea Imre3, Péter Ábrányi-Balogh1, György G Ferenczy1, Stanislav Gobec2, György M Keserű4.   

Abstract

Here we present WIDOCK, a virtual screening protocol that supports the selection of diverse electrophiles as covalent inhibitors by incorporating ligand reactivity towards cysteine residues into AutoDock4. WIDOCK applies the reactive docking method (Backus et al. in Nature 534:570-574, 2016) and extends it into a virtual screening tool by introducing facile experimental or computational parametrization and a ligand focused evaluation scheme together with a retrospective and prospective validation against various therapeutically relevant targets. Parameters accounting for ligand reactivity are derived from experimental reaction kinetic data or alternatively from computed reaction barriers. The performance of this docking protocol was first evaluated by investigating compound series with diverse warhead chemotypes against KRASG12C, MurA and cathepsin B. In addition, WIDOCK was challenged on larger electrophilic libraries screened against OTUB2 and NUDT7. These retrospective analyses showed high sensitivity in retrieving experimental actives, by also leading to superior ROC curves, AUC values and better enrichments than the standard covalent docking tool available in AutoDock4 when compound collections with diverse warheads were investigated. Finally, we applied WIDOCK for the prospective identification of covalent human MAO-A inhibitors acting via a new mechanism by binding to Cys323. The inhibitory activity of several predicted compounds was experimentally confirmed and the labelling of Cys323 was proved by subsequent MS/MS measurements. These findings demonstrate the usefulness of WIDOCK as a warhead-sensitive, covalent virtual screening protocol.

Entities:  

Keywords:  Covalent docking; Covalent inhibitors; Virtual screening; Warhead reactivity

Mesh:

Substances:

Year:  2021        PMID: 33458809      PMCID: PMC7904743          DOI: 10.1007/s10822-020-00371-5

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  67 in total

Review 1.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets.

Authors:  Olga Vasiljeva; Thomas Reinheckel; Christoph Peters; Dusan Turk; Vito Turk; Boris Turk
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

2.  A thorough benchmark of density functional methods for general main group thermochemistry, kinetics, and noncovalent interactions.

Authors:  Lars Goerigk; Stefan Grimme
Journal:  Phys Chem Chem Phys       Date:  2011-03-07       Impact factor: 3.676

3.  Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds.

Authors:  Bojana Mirković; Miha Renko; Samo Turk; Izidor Sosič; Zala Jevnikar; Nataša Obermajer; Dušan Turk; Stanislav Gobec; Janko Kos
Journal:  ChemMedChem       Date:  2011-05-20       Impact factor: 3.466

4.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

5.  Covalent docking using autodock: Two-point attractor and flexible side chain methods.

Authors:  Giulia Bianco; Stefano Forli; David S Goodsell; Arthur J Olson
Journal:  Protein Sci       Date:  2015-07-07       Impact factor: 6.725

6.  N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.

Authors:  Oscar M Bautista-Aguilera; Abdelouahid Samadi; Mourad Chioua; Katarina Nikolic; Slavica Filipic; Danica Agbaba; Elena Soriano; Lucía de Andrés; María Isabel Rodríguez-Franco; Stefano Alcaro; Rona R Ramsay; Francesco Ortuso; Matilde Yañez; José Marco-Contelles
Journal:  J Med Chem       Date:  2014-12-08       Impact factor: 7.446

Review 7.  Covalent inhibitors design and discovery.

Authors:  Stephane De Cesco; Jerry Kurian; Caroline Dufresne; Anthony K Mittermaier; Nicolas Moitessier
Journal:  Eur J Med Chem       Date:  2017-06-10       Impact factor: 6.514

8.  Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes.

Authors:  Lynn M McGregor; Meredith L Jenkins; Caitlin Kerwin; John E Burke; Kevan M Shokat
Journal:  Biochemistry       Date:  2017-06-16       Impact factor: 3.162

9.  Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin.

Authors:  T Skarzynski; A Mistry; A Wonacott; S E Hutchinson; V A Kelly; K Duncan
Journal:  Structure       Date:  1996-12-15       Impact factor: 5.006

10.  Comparative Evaluation of Covalent Docking Tools.

Authors:  Andrea Scarpino; György G Ferenczy; György M Keserű
Journal:  J Chem Inf Model       Date:  2018-06-22       Impact factor: 4.956

View more
  3 in total

Review 1.  Advances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition.

Authors:  Maycon Vinicius Damasceno de Oliveira; Renan Machado Furtado; Kauê S da Costa; Serhii Vakal; Anderson H Lima
Journal:  Front Mol Biosci       Date:  2022-07-20

Review 2.  Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices.

Authors:  Abdul-Quddus Kehinde Oyedele; Abdeen Tunde Ogunlana; Ibrahim Damilare Boyenle; Ayodeji Oluwadamilare Adeyemi; Temionu Oluwakemi Rita; Temitope Isaac Adelusi; Misbaudeen Abdul-Hammed; Oluwabamise Emmanuel Elegbeleye; Tope Tunji Odunitan
Journal:  Mol Divers       Date:  2022-09-04       Impact factor: 3.364

3.  Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors.

Authors:  Kai Zhu; Cui Li; Kingsley Y Wu; Christopher Mohr; Xun Li; Brian Lanman
Journal:  J Comput Aided Mol Des       Date:  2022-08-05       Impact factor: 4.179

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.